Denosumab for joints and bones

Current Rheumatology Reports

Volumn 11, Issue 3, 2009, Pages 196-201

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; METHOTREXATE; PLACEBO; VITAMIN D; ANTIRHEUMATIC AGENT; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DIVERTICULITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; JAW OSTEONECROSIS; LABYRINTHITIS; OSTEOPENIA; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; SINUSITIS; STOMACH CANCER; UPPER RESPIRATORY TRACT INFECTION; AGED; BONE; DRUG COMBINATION; DRUG EFFECT; FEMALE; JOINT; METABOLISM; MIDDLE AGED; OSTEOCLAST; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JOINTS; METHOTREXATE; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND;

EID: 70349571611     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0027-z     Document Type: Review

References (29)

1. A. Klibanski L. Adams-Campbell T. Bassford, et al. 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795 10.1001/jama.285.6.785
2. US Department of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
3. R. Burge B. Dawson-Hughes D.H. Solomon, et al. 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 475 17144789 10.1359/jbmr.061113 (Pubitemid 46797130)
4. International Osteoporosis Foundation: IOF Osteoporosis Teaching Slide Kit. Available at http://www.osteofound.org/health-professionals/teaching- resources/slide-kit.html. Accessed March 2006.
5. E. Dennison C. Cooper 2000 Epidemiology of osteoporotic fractures Horm Res 54 Suppl1 58 63 11146381 1:CAS:528:DC%2BD3MXhs12rsrs%3D
6. C. Cooper 1997 The crippling consequences of fractures and their impact on quality of life Am J Med 103 2A 12S 19S 9302893 10.1016/S0002-9343(97)90022-X 1:STN:280:DyaK2svkvVGltQ%3D%3D
7. N.C. Walsh T.N. Crotti S.R. Goldring E.M. Gravallese 2005 Rheumatic diseases: the effects of inflammation on bone Immunol Rev 208 228 251 16313352 10.1111/j.0105-2896.2005.00338.x 1:CAS:528:DC%2BD28Xks1ehsA%3D%3D
8. A. Kavanaugh 2007 Economic consequences of established rheumatoid arthritis and its treatment Best Pract Res Clin Rheumatol 21 929 942 17870036 10.1016/j.berh.2007.05.005 (Pubitemid 47377807)
9. P.J. Bekker D.L. Holloway A.S. Rasmussen, et al. 2004 A singledose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 1059 1066 15176987 10.1359/JBMR.040305 1:CAS:528:DC%2BD2cXlvFWrtr0%3D (Pubitemid 41110556)
10. P. Collin-Osdoby 2004 Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin Circ Res 95 1046 1057 15564564 10.1161/01.RES.0000149165.99974.12 1:CAS:528:DC%2BD2cXpvVGmtb0%3D (Pubitemid 39557891)
11. W.S. Simonet D.L. Lacey C.R. Dunstan, et al. 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319 9108485 10.1016/S0092-8674(00)80209-3 1:CAS:528:DyaK2sXislCgtLc%3D
12. L.C. Hofbauer M. Schoppet 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases JAMA 292 490 495 15280347 10.1001/jama.292.4.490 1:CAS:528:DC%2BD2cXmtFOmsbw%3D (Pubitemid 38988958)
13. P.J. Bekker D. Holloway A. Nakanishi, et al. 2001 The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 348 360 11204435 10.1359/jbmr.2001.16.2.348 1:CAS:528:DC%2BD3MXptlOquw%3D%3D
14. E.D. Lobo R.J. Hansen J.P. Balthasar 2004 Antibody pharmacokinetics and pharmacodynamics J Pharm Sci 93 2645 2668 15389672 10.1002/jps.20178 1:CAS:528:DC%2BD2cXpvV2isLk%3D (Pubitemid 39506617)
15. L. Tang A.M. Persky G. Hochhaus B. Meibohm 2004 Pharmacokinetic aspects of biotechnology products J Pharm Sci 93 2184 2204 15295780 10.1002/jps.20125 1:CAS:528:DC%2BD2cXnsVegur8%3D (Pubitemid 39129617)
16. M.C. Peterson B.J. Stouch S.W. Martin, et al. 2005 The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass J Bone Miner Res 20 Suppl1 S293
17. M.R. McClung E.M. Lewiecki S.B. Cohen, et al. 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 16495394 10.1056/NEJMoa044459 1:CAS:528:DC%2BD28Xhsl2gs7o%3D (Pubitemid 43290920)
18. E.M. Lewiecki P.D. Miller M.R. McClung, et al. 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density J Bone Miner Res 22 1832 1841 17708711 10.1359/jbmr.070809 1:CAS:528:DC%2BD2sXhsVyjtrjF (Pubitemid 351229299)
19. P.D. Miller M.A. Bolognese E.M. Lewiecki, et al. 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222 229 18539106 10.1016/j.bone.2008.04. 007 1:CAS:528:DC%2BD1cXosVOitrk%3D
20. H.G. Bone M.A. Bolognese C.K. Yuen, et al. 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157 18381571 10.1210/jc.2007-2814 1:CAS:528:DC%2BD1cXntFamtrg%3D (Pubitemid 351831529)
21. J.P. Brown R.L. Prince C. Deal, et al. 2009 Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153 161 18767928 10.1359/jbmr.0809010 1:CAS:528:DC%2BD1MXht1yrtbc%3D
22. Kendler DL, Benhamou CL, Brown JP, et al.: Effects of denosumab vs alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate. J Bone Miner Res 2008, S473.
23. S.R. Cummings M.R. McClung C. Christiansen, et al. 2008 A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial J Bone Miner Res 23 Suppl1 S80
24. Amgen Inc: Form 8-K. Available at http://investors.amgen.com/phoenix. zhtml?c=61656&p=irol-sec. Accessed September 2008.
25. S.B. Cohen R.K. Dore N.E. Lane, et al. 2008 Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis Rheum 58 1299 1309 18438830 10.1002/art.23417 1:CAS:528:DC%2BD1cXms1ehu70%3D (Pubitemid 351705919)
26. F.C. Arnett S.M. Edworthy D.A. Bloch, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 3358796 10.1002/art.1780310302 1:STN:280:DyaL1c7pt1Ohsg%3D%3D
27. F. McQueen M. Lassere J. Edmonds, et al. 2003 OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module J Rheumatol 30 1387 1392 12784423
28. D. van der Heijde 2000 How to read radiographs according to the Sharp/van der Heijde method J Rheumatol 27 261 263 10648051
29. S.B. Cohen E.M. Lewiecki Y. Liu, et al. 2005 Phase 2 study of denosumab (AMG 162) in postmenopausal women: subanalyses and supplemental safety J Bone Miner Res 20 Suppl1 S295